Business
Appointment of Dr Claudio Carini
Appointment of Dr Claudio Carini.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \nRNS Number : 6713W Oxford BioDynamics PLC 13 February 2017 \n\n \n13 February 2017\n \nOxford BioDynamics Plc\n(\"OBD\" or the \"Company\")\n \nOxford BioDynamics appoints Dr Claudio Carini as an Advisor\n \nOxford BioDynamics Plc (AIM: OBD), a revenue-generating biotechnology company focused on the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry, announces that Dr Claudio Carini has been appointed as an Advisor, effective immediately. As part of his role, Claudio will sit on the Company's Scientific Advisory Panel.\n \nClaudio has over 20 years' experience in immunology, drug development, personalised medicine, and biomarkers. Previously, he was Global Head of Clinical Immunology & Biomarkers at Pfizer, and currently holds an Honorary Faculty position at the King's College School of Medicine, London. Claudio has also consulted and sat on many distinguished international advisory boards and committees including the Medical Research Council (UK), F-NIH Biomarkers Consortium, Innovative Medicine Initiative (IMI-EU) and the PML Consortium.\n \nPrior to joining Pfizer, Claudio has served in faculty roles at Harvard University, Johns Hopkins University, University College London and Rome University. Later in his career he held different senior roles at Wyeth, Novartis, Fresenius and Roche. He has also authored over two hundred papers in peer reviewed journals and co-edited three books in the field of personalised medicine. Claudio has received a doctorate in Medicine from Italy and a Ph.D from the University College London. Claudio has also specialist diplomas in Clinical Immunology and Respiratory Medicine from the University of Rome and has also been awarded a fellowship of the Royal College of Pathologists, London.\n \nChristian Hoyer Millar, CEO of Oxford BioDynamics said:\n \n\"We are delighted that Claudio will be joining the Company as an Advisor. His strong passion in the application of biomarkers in translational medicine and personalised healthcare, and impressive track record in this field will be hugely beneficial to Oxford BioDynamics at this exciting time in our development.\n \nHis previous experience in the US will be of great value to us as we continue to build and expand relationships wit...